Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Direct...
February 08 2018 - 8:00AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”
or the “Company”), a clinical stage biopharmaceutical company
focused on the global immunology market, today announced the
appointment of Joseph P. “Jay” Hagan. to its board of directors.
Mr. Hagan is currently the President and Chief Executive Officer of
Regulus Therapeutics.
“Jay brings a wealth of business development and commercial
experience to our Board,” said Richard M. Glickman, Chief Executive
Officer and Chairman of the Board of Aurinia. “He has made
significant contributions to the biotechnology industry during his
career, and his strategic expertise will prove extremely valuable
in the board room.”
Mr. Hagan joined Regulus in January 2016 as Chief Operating
Officer, Principal Financial Officer and Principal Accounting
Officer and was appointed to President and Chief Executive Officer
in May 2017. Mr. Hagan’s career includes roles as the Executive
Vice President, Chief Financial Officer and Chief Business Officer
of Orexigen Therapeutics, Inc., Managing Director of Amgen Ventures
and head of corporate development for Amgen Inc. Mr. Hagan has led
numerous strategic and financing transactions including the
acquisitions of Immunex and Tularik and the spinout of Novantrone
and Relyspa, as well as many other business development efforts
totaling over $15 billion in value. Before joining Amgen, Mr. Hagan
spent five years in the bioengineering labs at Genzyme and Advanced
Tissue Sciences. Mr. Hagan currently serves on the board of
directors of Zosano Pharma, a publicly traded biotechnology
company. He received an M.B.A. from Northeastern University and a
B.S. in Physiology and Neuroscience from the University of
California, San Diego.
"Aurinia’s commitment to addressing the significant unmet
medical need in lupus nephritis with the promising results in Phase
II clinical studies of voclosporin is highly encouraging for
patients suffering from this debilitating disease,” added Jay
Hagan. “I look forward to working together with the other board
directors alongside this exceptional management team as we pursue a
successful future for the company.”
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The company
is currently developing voclosporin, an investigational drug, for
the treatment of LN, FSGS, MCD and DES. The company is
headquartered in Victoria, BC and focuses its development efforts
globally. For further information, see our website at
www.auriniapharma.com.
Forward Looking StatementsThis press release contains
forward-looking statements, including statements related to
voclosporin’s promising results in Phase II clinical studies ,
Aurinia’s corporate strategy and Mr. Hagan’s expected impact on
Aurinia’s progress. It is possible that such results or conclusions
may change based on further analyses of these data. Words such as
"plans," "intends," “may,” "will," "believe," and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Aurinia’s current
expectations. Forward-looking statements involve risks and
uncertainties. Aurinia’s actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risk that
Aurinia’s analyses, assessment and conclusions of the results of
its clinical studies may change based on further analyses, the risk
that Aurinia will not successfully complete its clinical programs
and the risk that Aurinia’s clinical studies for voclosporin may
not lead to regulatory approval. These and other risk factors are
discussed under "Risk Factors" and elsewhere in Aurinia’s Annual
Information Form for the year ended December 31, 2016 filed with
Canadian securities authorities and available at www.sedar.com and
on Form 40-F with the U.S. Securities Exchange Commission and
available at www.sec.gov, each as updated by subsequent filings,
including filings on Form 6-K. Aurinia expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Aurinia's expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based, except as required by law.
We seek safe harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180208005431/en/
Aurinia Pharmaceuticals Inc.Investor:Celia EconomidesVP,
Corporate & Public
AffairsIR@auriniapharma.comorMedia:Christopher Hippolyte,
212-364-0458Christopher.hippolyte@inventivhealth.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024